Emyria Limited (ASX:EMD)
Australia · Delayed Price · Currency is AUD 0.0460
-0.0030 (-6.12%)
Aug 1, 2025, 4:10 PM AEST
Theseus Pharmaceuticals Revenue
Emyria had revenue of 658.20K AUD in the half year ending December 31, 2024, a decrease of -10.10%. This brings the company's revenue in the last twelve months to 1.77M, down -9.16% year-over-year. In the fiscal year ending June 30, 2024, Emyria had annual revenue of 2.20M with 38.32% growth.
Revenue (ttm)
1.77M
Revenue Growth
-9.16%
P/S Ratio
15.88
Revenue / Employee
n/a
Employees
n/a
Market Cap
28.13M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2024 | 2.20M | 610.25K | 38.32% |
| Jun 30, 2023 | 1.59M | -229.93K | -12.62% |
| Jun 30, 2022 | 1.82M | -153.51K | -7.77% |
| Jun 30, 2021 | 1.98M | 962.46K | 94.97% |
| Jun 30, 2020 | 1.01M | 903.54K | 822.08% |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| CSL Limited | 24.61B |
| Pro Medicus | 184.58M |
| Cochlear | 2.31B |
| Sonic Healthcare | 9.33B |
| Ramsay Health Care | 17.12B |
| Telix Pharmaceuticals | 783.21M |
| Ansell | 3.00B |
| Mesoblast | 9.16M |